ArticleFrontiers in oncology2026
Modeling ovarian cancer chemoresistance: establishment of murine ID8 sublines and elucidation of adaptive mechanisms.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acquired resistance to platinum-taxane chemotherapy is a major cause of treatment failure in ovarian cancer (OC). Methods: Paclitaxel- and carboplatin-resistant sublines (ID8-T and ID8-C) were established by intermittent drug exposure from parental ID8 cells. Cellular morphology was assessed by Giemsa staining. Cell viability was determined using CCK-8 and colony formation assays. Flow cytometry was employed to analyze cell cycle distribution and apoptosis rate. Intracellular drug concentration was quantified by high-performance liquid chromatography (HPLC). Reactive oxygen species (ROS) levels were detected with a fluorescent probe, and protein expression profiles were analyzed by Western blotting. Results: Both ID8-T and ID8-C exhibited significant resistance to their inducing agents, with resistance indices of 4.54 and 2.21, respectively, and demonstrated cross-resistance phenotype. They showed enhanced clonogenic survival and attenuated drug-induced cell cycle arrest and apoptosis. Mechanistically, resistant cells exhibited reduced intracellular drug accumulation, maintained lower ROS levels, and displayed altered expression of key regulatory proteins. These included sustained pro-survival signals (MCM2, STAT3, 4E-BP1), impaired apoptotic execution (reduced cleaved caspase-3/PARP/LaminA/C), upregulation of the drug efflux pump ABCB1, and dysregulated mitochondrial fission machinery (downregulated MFF). Conclusion: We have established and characterized two novel murine OC chemoresistance models. The resistant phenotypes of ID8-T and ID8-C sublines are associated with a multifaceted adaptive signature involving enhanced drug efflux, evasion of cell cycle arrest and apoptosis, reduced ROS levels, and altered expression of proteins related to mitochondrial fission. These well-characterized syngeneic models provide valuable tools for future mechanistic and therapeutic studies aimed at overcoming chemotherapy resistance in OC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.